Metrics as of 10/13/2026, 06:54 PM (Berlin time), refresh in progress.
Lineage Cell Therapeutics Stock
Lineage Cell Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Brian Culley
- Employees
- 75
- Market cap
- $226 M
- IPO
- 05/03/1992
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical…
Lineage Cell Therapeutics stock: price history
1D
-4.8%
1W
-3.2%
1M
-10.1%
6M
-42.9%
YTD
-45.6%
1Y
-48.7%
2Y
+6.2%
5Y
-62.2%
10Y
-74.3%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~5% weaker price swings than usual
Ask the agents about Lineage Cell Therapeutics
Analyst assessment of Lineage Cell Therapeutics
0
STRONG BUY
5
BUY
0
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 14/07/2026
Lineage Cell Therapeutics stock metrics
P/E
-6.48
P/B
3.72
EV/EBITDA
-5.22
RETURN ON EQUITY
2.4%
NET MARGIN
138.6%
DEBT/EQUITY
0.04
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
94.9%
FLOAT SHARES
236,532,477
AVG. DAILY VOLUME (30D)
1,491,686
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Lineage Cell Therapeutics stock
What does Lineage Cell Therapeutics do?
Lineage Cell Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Brian Culley, the company employs around 75 people.
The IPO was on 05/03/1992; the stock trades on AMEX under the ticker LCTX.
What do analysts say about Lineage Cell Therapeutics stock?
5 analysts rate the stock, the consensus is Buy (as of 14/07/2026).
This is an external assessment, not a statement by Market Jury.
When does Lineage Cell Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -5% stronger than usual.
Does Lineage Cell Therapeutics pay a dividend?
Yes. The last dividend was US$0.08 per share.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Lineage Cell Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Lineage Cell Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Lineage Cell Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.